Business Context and Reporting Period
This Form 8-K was filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on May 13, 2021. The report details the entry into a material definitive agreement regarding the company's principal executive offices located at 259 East Grand Avenue in South San Francisco, California.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the amended lease agreement:
- Base Rent (Extension Term): $52,611 per month.
- Base Rent (Optional Extension Term): $54,189 per month.
- Lease Term Extension: 12 months, expiring July 15, 2022.
- Optional Renewal: Additional 12 months, expiring July 15, 2023.
- Space Expansion: Approximately 221 square feet added to the premises.
Material Changes
The material change reported is the execution of a Third Amendment to the Sub-Sublease with Verily Life Sciences LLC. This amendment modifies the existing lease by expanding the leased space and extending the lease term by one year with an option for a second year.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on financial performance, or discussion of risks beyond the standard incorporation of the lease terms. The document notes that the summary of the amendment is qualified by reference to the full agreement, which will be filed in the subsequent Form 10-Q.
Investor Verification Checklist
- Verify the total annualized cost of the lease extension and optional renewal against the company's current cash position.
- Confirm the operational necessity of the 221 square foot expansion.
- Review the full Third Amendment text in the upcoming Form 10-Q for any hidden clauses or termination rights.
- Note the discrepancy between the requested company name (Quince Therapeutics) and the filing registrant (Cortexyme, Inc.).